Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Spyre (SYRE) PT Raised to $107 at Stifel
May 5, 2026 4:26 PM EDTStifel analyst Alex Thompson raised the price target on Spyre (NASDAQ: SYRE) to $107.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Following best-in-class UC PoC data for SPY001 (a4B7), SYRE is well-positioned heading into additional PoC cohorts for... More
